Literature DB >> 22271153

Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.

Milos D Ikonomovic1, Eric E Abrahamson, Julie C Price, Ronald L Hamilton, Chester A Mathis, William R Paljug, Manik L Debnath, Anne D Cohen, Katsuyoshi Mizukami, Steven T DeKosky, Oscar L Lopez, William E Klunk.   

Abstract

Amyloid-β (Aβ) deposits are detectable in the brain in vivo using positron emission tomography (PET) and [C-11]-labeled Pittsburgh Compound B ([C-11]PiB); however, the sensitivity of this technique is not well understood. In this study, we examined Aβ pathology in an individual who had clinical diagnoses of probable dementia with Lewy bodies and possible Alzheimer's disease (AD) but with no detectable [C-11]PiB PET retention ([C-11]PiB(-)) when imaged 17 months prior to death. Brain samples were processed in parallel with region-matched samples from an individual with a clinical diagnosis of probable AD and a positive [C-11]PiB PET scan ([C-11]PiB(+)) when imaged 10 months prior to death. In the [C-11]PiB(-) case, Aβ plaques were sparse, occupying less than 2% cortical area, and were weakly labeled with 6-CN-PiB, a highly fluorescent derivative of PiB. In contrast, Aβ plaques occupied up to 12% cortical area in the [C-11]PiB(+) case, and were intensely labeled with 6-CN-PIB. The [C-11]PiB(-) case had low levels of [H-3]PiB binding (< 100 pmol/g) and Aβ1-42 (< 500 pmol/g) concentration except in the frontal cortex where Aβ1-42 values (788 pmol/g) approached cortical values in the [C-11]PiB(+) case (800-1, 700 pmol/g). In several cortical regions of the [C-11]PiB(-) case, Aβ1-40 levels were within the range of cortical Aβ1-40 values in the [C-11]PiB(+) case. Antemortem [C-11]PiB DVR values correlated well with region-matched postmortem measures of Aβ1-42 and Aβ1-40 in the [C-11]PiB(+), and with Aβ1-42 only in the [C-11]PiB(-) case. The low ratios of [H-3]PiB binding levels to Aβ concentrations and 6-CN-PiB to Aβ plaque loads in the [C-11]PiB(-) case indicate that Aβ pathology in the brain may be associated with low or undetectable levels of [C-11]PiB retention. Studies in greater numbers of [C-11]PiB PET autopsy cases are needed to define the Aβ concentration and [H-3]PiB binding levels required to produce a positive [C-11]PiB PET signal.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271153      PMCID: PMC3383058          DOI: 10.1007/s00401-012-0943-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  50 in total

1.  Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP.

Authors:  A Kamal; A Almenar-Queralt; J F LeBlanc; E A Roberts; L S Goldstein
Journal:  Nature       Date:  2001-12-06       Impact factor: 49.962

2.  X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology.

Authors:  S D Styren; R L Hamilton; G C Styren; W E Klunk
Journal:  J Histochem Cytochem       Date:  2000-09       Impact factor: 2.479

3.  Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging.

Authors:  Yanjun Wu; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2002-12       Impact factor: 6.200

4.  Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain.

Authors:  W E Klunk; Y Wang; G F Huang; M L Debnath; D P Holt; C A Mathis
Journal:  Life Sci       Date:  2001-08-17       Impact factor: 5.037

5.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography.

Authors:  M A Mintun; M E Raichle; M R Kilbourn; G F Wooten; M J Welch
Journal:  Ann Neurol       Date:  1984-03       Impact factor: 10.422

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain.

Authors:  Chester A Mathis; Brian J Bacskai; Stephen T Kajdasz; Megan E McLellan; Matthew P Frosch; Bradley T Hyman; Daniel P Holt; Yanming Wang; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  Bioorg Med Chem Lett       Date:  2002-02-11       Impact factor: 2.823

8.  Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study.

Authors:  D S Wolf; M Gearing; D A Snowdon; H Mori; W R Markesbery; S S Mirra
Journal:  Alzheimer Dis Assoc Disord       Date:  1999 Oct-Dec       Impact factor: 2.703

9.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

10.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

View more
  42 in total

Review 1.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

Review 2.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 3.  Amyloid-β positron emission tomography imaging probes: a critical review.

Authors:  Vladimir Kepe; Mateen C Moghbel; Bengt Långström; Habib Zaidi; Harry V Vinters; Sung-Cheng Huang; Nagichettiar Satyamurthy; Doris Doudet; Eyal Mishani; Robert M Cohen; Poul F Høilund-Carlsen; Abass Alavi; Jorge R Barrio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine.

Authors:  Jan Booij; Javier Arbizu; Jacques Darcourt; Swen Hesse; Flavio Nobili; Pierre Payoux; Sabina Pappatà; Klaus Tatsch; Zuzana Walker; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07       Impact factor: 9.236

Review 5.  Molecular imaging of Alzheimer disease pathology.

Authors:  K Kantarci
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-06       Impact factor: 3.825

6.  Mild to moderate Alzheimer dementia with insufficient neuropathological changes.

Authors:  Alberto Serrano-Pozo; Jing Qian; Sarah E Monsell; Deborah Blacker; Teresa Gómez-Isla; Rebecca A Betensky; John H Growdon; Keith A Johnson; Matthew P Frosch; Reisa A Sperling; Bradley T Hyman
Journal:  Ann Neurol       Date:  2014-04-08       Impact factor: 10.422

7.  Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain.

Authors:  Ian Diner; Jeromy Dooyema; Marla Gearing; Lary C Walker; Nicholas T Seyfried
Journal:  Bioconjug Chem       Date:  2017-09-22       Impact factor: 4.774

Review 8.  Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.

Authors:  Sam Gandy; Steven T DeKosky
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

Review 9.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

10.  A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain.

Authors:  Sergey V Matveev; Hans Peter Spielmann; Brittney M Metts; Jing Chen; Fredrick Onono; Haining Zhu; Stephen W Scheff; Lary C Walker; Harry LeVine
Journal:  J Neurochem       Date:  2014-07-28       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.